Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence

By K. Mohd Hanafiah, Justina Groeger, Abraham D. Flaxman, S. Wiersma. Hepatology, 2013

2,563 citations recorded by the source corpus.

Subfields: Emergency Medicine, Hepatology, Oncology

View Paper: https://www.semanticscholar.org/paper/df8ef70a234a2e0f2d5ffae841595817bd5d6295

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. E. Gower
2. K. Razavi-Shearer
3. A. Jemal
4. C. Estes
5. Elizabeth E. Ward
6. S. Blach
7. H. Razavi

In Oncology

1. R. Siegel
2. A. Jemal
3. Elizabeth E. Ward
4. Lindsey A. Torre
5. J. Feld
6. K. Miller
7. F. Bray
8. J. Ferlay

Citations in the corpus

• Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. (2015, background): “Neutrophil count 500 to <750 per mm3 0 4 (1)”
• Global Cancer in Women: Burden and Trends (2017, background): “The cancer burden among women is high in both HICs and LMICs, and it is expected to increase as populations grow and age and as risk factors associated with urbanization increase in prevalence.”
• Global epidemiology and genotype distribution of the hepatitis C virus infection. (2014, background): “7% (regional estimate) [14] in previous analyses.”
• Global Distribution and Prevalence of Hepatitis C Virus Genotypes (2014, methodology): “*Regional HCV seroprevalence data from Hanafiah et al.(2) HEPATOLOGY, Vol.”